際際滷shows by User: PaulDRennert / http://www.slideshare.net/images/logo.gif 際際滷shows by User: PaulDRennert / Sun, 16 Feb 2025 20:06:33 GMT 際際滷Share feed for 際際滷shows by User: PaulDRennert PD1 x VEGF bispecific landscape: examining Hope versus Hype /slideshow/pd1-x-vegf-bispecific-landscape-examining-hope-versus-hype/275711434 bispecifics-pd1xvegf-250216200633-873977ba
There were waves of interest in this therapeutic space at ASCO in June 2024 and around the JP Morgan healthcare conference in January 2025. Here we take a look at the hope and the hype behind the PD1/VEGF bispecific therapeutics.]]>
There were waves of interest in this therapeutic space at ASCO in June 2024 and around the JP Morgan healthcare conference in January 2025. Here we take a look at the hope and the hype behind the PD1/VEGF bispecific therapeutics.]]> Sun, 16 Feb 2025 20:06:33 GMT /slideshow/pd1-x-vegf-bispecific-landscape-examining-hope-versus-hype/275711434 PaulDRennert@slideshare.net(PaulDRennert) PD1 x VEGF bispecific landscape: examining Hope versus Hype PaulDRennert There were waves of interest in this therapeutic space at ASCO in June 2024 and around the JP Morgan healthcare conference in January 2025. Here we take a look at the hope and the hype behind the PD1/VEGF bispecific therapeutics. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/bispecifics-pd1xvegf-250216200633-873977ba-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> There were waves of interest in this therapeutic space at ASCO in June 2024 and around the JP Morgan healthcare conference in January 2025. Here we take a look at the hope and the hype behind the PD1/VEGF bispecific therapeutics.
PD1 x VEGF bispecific landscape: examining Hope versus Hype from Paul D. Rennert
]]> 1092 0 https://cdn.slidesharecdn.com/ss_thumbnails/bispecifics-pd1xvegf-250216200633-873977ba-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 ALETA CNS metastasis program 8 July 2020 /slideshow/aleta-cns-metastasis-program-8-july-2020/236831647 octsjuly2020-200712143603
際際滷 deck used for video presentation to the OCTS conference. Her2-positive CNS metastases plague refractory breast cancer patients. Here we present our wholly novel approach to cell therapy for the treatment of these patients. #celltherapy #oncology #breastcancer]]>
際際滷 deck used for video presentation to the OCTS conference. Her2-positive CNS metastases plague refractory breast cancer patients. Here we present our wholly novel approach to cell therapy for the treatment of these patients. #celltherapy #oncology #breastcancer]]> Sun, 12 Jul 2020 14:36:03 GMT /slideshow/aleta-cns-metastasis-program-8-july-2020/236831647 PaulDRennert@slideshare.net(PaulDRennert) ALETA CNS metastasis program 8 July 2020 PaulDRennert 際際滷 deck used for video presentation to the OCTS conference. Her2-positive CNS metastases plague refractory breast cancer patients. Here we present our wholly novel approach to cell therapy for the treatment of these patients. #celltherapy #oncology #breastcancer <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/octsjuly2020-200712143603-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> 際際滷 deck used for video presentation to the OCTS conference. Her2-positive CNS metastases plague refractory breast cancer patients. Here we present our wholly novel approach to cell therapy for the treatment of these patients. #celltherapy #oncology #breastcancer
ALETA CNS metastasis program 8 July 2020 from Paul D. Rennert
]]> 1061 0 https://cdn.slidesharecdn.com/ss_thumbnails/octsjuly2020-200712143603-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 Rennert et al. ASH 2019 talk /slideshow/rennert-et-al-ash-2019-talk/204579591 rennertash2019-191211193951
Aleta Biotherapeutics biologic bridging protein for the treatment of patients relapsing from CAR-CD19 therapies, presented at #ASH19]]>
Aleta Biotherapeutics biologic bridging protein for the treatment of patients relapsing from CAR-CD19 therapies, presented at #ASH19]]> Wed, 11 Dec 2019 19:39:51 GMT /slideshow/rennert-et-al-ash-2019-talk/204579591 PaulDRennert@slideshare.net(PaulDRennert) Rennert et al. ASH 2019 talk PaulDRennert Aleta Biotherapeutics biologic bridging protein for the treatment of patients relapsing from CAR-CD19 therapies, presented at #ASH19 <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/rennertash2019-191211193951-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> Aleta Biotherapeutics biologic bridging protein for the treatment of patients relapsing from CAR-CD19 therapies, presented at #ASH19
Rennert et al. ASH 2019 talk from Paul D. Rennert
]]> 424 5 https://cdn.slidesharecdn.com/ss_thumbnails/rennertash2019-191211193951-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 Aleta Bio CAR-TCR Summit 11 Sept 2019 /slideshow/aleta-bio-cartcr-summit-11-sept-2019/171162555 aletacar-tcrsept2019-190912114940
Link to my presentation given at the CAR-TCR Summit in Boston. Great meeting, great crowd and excellent questions form the audience - Fun! ]]>
Link to my presentation given at the CAR-TCR Summit in Boston. Great meeting, great crowd and excellent questions form the audience - Fun! ]]> Thu, 12 Sep 2019 11:49:40 GMT /slideshow/aleta-bio-cartcr-summit-11-sept-2019/171162555 PaulDRennert@slideshare.net(PaulDRennert) Aleta Bio CAR-TCR Summit 11 Sept 2019 PaulDRennert Link to my presentation given at the CAR-TCR Summit in Boston. Great meeting, great crowd and excellent questions form the audience - Fun! <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/aletacar-tcrsept2019-190912114940-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> Link to my presentation given at the CAR-TCR Summit in Boston. Great meeting, great crowd and excellent questions form the audience - Fun!
Aleta Bio CAR-TCR Summit 11 Sept 2019 from Paul D. Rennert
]]> 1243 2 https://cdn.slidesharecdn.com/ss_thumbnails/aletacar-tcrsept2019-190912114940-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 Biological Goals for Novel Immune Checkpoints /slideshow/biological-goals-for-novel-immune-checkpoints/155725124 iothread-190715190136
Immune Checkpoint discovery yielded remarkable therapeutics (anti-CTLA4, anti-PD-1) but has more recently stalled out. Here I explore some of the issues the field has uncovered. Presented at the ICI-IO conference in March 2019. F]]>
Immune Checkpoint discovery yielded remarkable therapeutics (anti-CTLA4, anti-PD-1) but has more recently stalled out. Here I explore some of the issues the field has uncovered. Presented at the ICI-IO conference in March 2019. F]]> Mon, 15 Jul 2019 19:01:36 GMT /slideshow/biological-goals-for-novel-immune-checkpoints/155725124 PaulDRennert@slideshare.net(PaulDRennert) Biological Goals for Novel Immune Checkpoints PaulDRennert Immune Checkpoint discovery yielded remarkable therapeutics (anti-CTLA4, anti-PD-1) but has more recently stalled out. Here I explore some of the issues the field has uncovered. Presented at the ICI-IO conference in March 2019. F <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/iothread-190715190136-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> Immune Checkpoint discovery yielded remarkable therapeutics (anti-CTLA4, anti-PD-1) but has more recently stalled out. Here I explore some of the issues the field has uncovered. Presented at the ICI-IO conference in March 2019. F
Biological Goals for Novel Immune Checkpoints from Paul D. Rennert
]]> 556 5 https://cdn.slidesharecdn.com/ss_thumbnails/iothread-190715190136-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 Io combos and the big stick /slideshow/io-combos-and-the-big-stick/75387012 iocombosandthebigstick-170425121402
How pharma is advancing, why small biotechs best carry a big stick and other lessons from the immunooncology combo landscape - ]]>
How pharma is advancing, why small biotechs best carry a big stick and other lessons from the immunooncology combo landscape - ]]> Tue, 25 Apr 2017 12:14:01 GMT /slideshow/io-combos-and-the-big-stick/75387012 PaulDRennert@slideshare.net(PaulDRennert) Io combos and the big stick PaulDRennert How pharma is advancing, why small biotechs best carry a big stick and other lessons from the immunooncology combo landscape - <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/iocombosandthebigstick-170425121402-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> How pharma is advancing, why small biotechs best carry a big stick and other lessons from the immunooncology combo landscape -
Io combos and the big stick from Paul D. Rennert
]]> 1912 5 https://cdn.slidesharecdn.com/ss_thumbnails/iocombosandthebigstick-170425121402-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 3768 rennert /slideshow/3768-rennert/74664556 3768rennert-170407180921
Aleta Biotherapeutics poster from AACR 2017, abstract #3768]]>
Aleta Biotherapeutics poster from AACR 2017, abstract #3768]]> Fri, 07 Apr 2017 18:09:20 GMT /slideshow/3768-rennert/74664556 PaulDRennert@slideshare.net(PaulDRennert) 3768 rennert PaulDRennert Aleta Biotherapeutics poster from AACR 2017, abstract #3768 <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/3768rennert-170407180921-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> Aleta Biotherapeutics poster from AACR 2017, abstract #3768
3768 rennert from Paul D. Rennert
]]> 1209 2 https://cdn.slidesharecdn.com/ss_thumbnails/3768rennert-170407180921-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 RATIONAL COMBINATION IMMUNOTHERAPY: The best of ASCO16 clinical data /PaulDRennert/rational-combination-immunotherapy-the-best-of-asco16-clinical-data rennertiocomboreviewfinalsmall-160910142925
Presented at the Immuno-Oncology Summit August 31, 2016. Studies from ASCO16 on immune checkpoint combinations, immune checkpoints with other therapies, immune checkpoints and CAR T, and other studies that enrich our understanding of immuno-oncology as a broad-based discipline for cancer therapy.]]>
Presented at the Immuno-Oncology Summit August 31, 2016. Studies from ASCO16 on immune checkpoint combinations, immune checkpoints with other therapies, immune checkpoints and CAR T, and other studies that enrich our understanding of immuno-oncology as a broad-based discipline for cancer therapy.]]> Sat, 10 Sep 2016 14:29:25 GMT /PaulDRennert/rational-combination-immunotherapy-the-best-of-asco16-clinical-data PaulDRennert@slideshare.net(PaulDRennert) RATIONAL COMBINATION IMMUNOTHERAPY: The best of ASCO16 clinical data PaulDRennert Presented at the Immuno-Oncology Summit August 31, 2016. Studies from ASCO16 on immune checkpoint combinations, immune checkpoints with other therapies, immune checkpoints and CAR T, and other studies that enrich our understanding of immuno-oncology as a broad-based discipline for cancer therapy. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/rennertiocomboreviewfinalsmall-160910142925-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> Presented at the Immuno-Oncology Summit August 31, 2016. Studies from ASCO16 on immune checkpoint combinations, immune checkpoints with other therapies, immune checkpoints and CAR T, and other studies that enrich our understanding of immuno-oncology as a broad-based discipline for cancer therapy.
RATIONAL COMBINATION IMMUNOTHERAPY: The best of ASCO16 clinical data from Paul D. Rennert
]]> 2085 3 https://cdn.slidesharecdn.com/ss_thumbnails/rennertiocomboreviewfinalsmall-160910142925-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 Im vacs 2015 rennert v2 /slideshow/im-vacs-2015-rennert-v2/52110255 imvacs2015rennertv2-150826211809-lva1-app6891
Some cancers are very resistant to immunotherapy. Here I talk about two of those, and speculate on the role of the tumor microenvironment in blocking productive anti-tumor immunity.]]>
Some cancers are very resistant to immunotherapy. Here I talk about two of those, and speculate on the role of the tumor microenvironment in blocking productive anti-tumor immunity.]]> Wed, 26 Aug 2015 21:18:09 GMT /slideshow/im-vacs-2015-rennert-v2/52110255 PaulDRennert@slideshare.net(PaulDRennert) Im vacs 2015 rennert v2 PaulDRennert Some cancers are very resistant to immunotherapy. Here I talk about two of those, and speculate on the role of the tumor microenvironment in blocking productive anti-tumor immunity. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/imvacs2015rennertv2-150826211809-lva1-app6891-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> Some cancers are very resistant to immunotherapy. Here I talk about two of those, and speculate on the role of the tumor microenvironment in blocking productive anti-tumor immunity.
Im vacs 2015 rennert v2 from Paul D. Rennert
]]> 2635 16 https://cdn.slidesharecdn.com/ss_thumbnails/imvacs2015rennertv2-150826211809-lva1-app6891-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 The immune checkpoint landscape in 2015: combination therapy /slideshow/the-immune-checkpoint-landscape-in-2015-combination-therapy/46609811 theimmunecheckpointlandscape-150403063202-conversion-gate01
A comprehensive workshop presentation on approved and developing therapeutics in immuno-oncology, presented at ICI Boston 2015]]>
A comprehensive workshop presentation on approved and developing therapeutics in immuno-oncology, presented at ICI Boston 2015]]> Fri, 03 Apr 2015 06:32:01 GMT /slideshow/the-immune-checkpoint-landscape-in-2015-combination-therapy/46609811 PaulDRennert@slideshare.net(PaulDRennert) The immune checkpoint landscape in 2015: combination therapy PaulDRennert A comprehensive workshop presentation on approved and developing therapeutics in immuno-oncology, presented at ICI Boston 2015 <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/theimmunecheckpointlandscape-150403063202-conversion-gate01-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> A comprehensive workshop presentation on approved and developing therapeutics in immuno-oncology, presented at ICI Boston 2015
The immune checkpoint landscape in 2015: combination therapy from Paul D. Rennert
]]> 40626 18 https://cdn.slidesharecdn.com/ss_thumbnails/theimmunecheckpointlandscape-150403063202-conversion-gate01-thumbnail.jpg?width=120&height=120&fit=bounds presentation 000000 http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 Immunotherapy: Novel Immunomodulatory Targets /slideshow/rennert-immunotherapy-and-immunomodulatory-2014/37952092 rennertimvacs2014-140813083534-phpapp02
An approach to discovering new immunotherapy targets for oncology is introduced and examples presented. New programs from biotech and pharma are discussed.]]>
An approach to discovering new immunotherapy targets for oncology is introduced and examples presented. New programs from biotech and pharma are discussed.]]> Wed, 13 Aug 2014 08:35:33 GMT /slideshow/rennert-immunotherapy-and-immunomodulatory-2014/37952092 PaulDRennert@slideshare.net(PaulDRennert) Immunotherapy: Novel Immunomodulatory Targets PaulDRennert An approach to discovering new immunotherapy targets for oncology is introduced and examples presented. New programs from biotech and pharma are discussed. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/rennertimvacs2014-140813083534-phpapp02-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> An approach to discovering new immunotherapy targets for oncology is introduced and examples presented. New programs from biotech and pharma are discussed.
Immunotherapy: Novel Immunomodulatory Targets from Paul D. Rennert
]]> 6444 5 https://cdn.slidesharecdn.com/ss_thumbnails/rennertimvacs2014-140813083534-phpapp02-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 https://cdn.slidesharecdn.com/profile-photo-PaulDRennert-48x48.jpg?cb=1740939934 I am a top-tier Biotechnology Investigator and Executive with extensive strategic and leadership experience and demonstrated success in bench to IND development of small molecule and biologic drugs for oncology, autoimmunity, chronic inflammation and fibrosis. I have deep experience in therapeutic area analysis and strategic development, opportunity assessment, due diligence, and alignment of research, commercial and clinical strategies. My recent accomplishments include working intensively with CoStim Pharmaceuticals' executive team to prioritize and launch that company's Cancer Immunotherapeutics portfolio. More recently I embedded with X-Chem Inc to create X-Rx Discovery, an asset-cent... http://www.sugarconebiotech.com https://cdn.slidesharecdn.com/ss_thumbnails/bispecifics-pd1xvegf-250216200633-873977ba-thumbnail.jpg?width=320&height=320&fit=bounds slideshow/pd1-x-vegf-bispecific-landscape-examining-hope-versus-hype/275711434 PD1 x VEGF bispecific ... https://cdn.slidesharecdn.com/ss_thumbnails/octsjuly2020-200712143603-thumbnail.jpg?width=320&height=320&fit=bounds slideshow/aleta-cns-metastasis-program-8-july-2020/236831647 ALETA CNS metastasis p... https://cdn.slidesharecdn.com/ss_thumbnails/rennertash2019-191211193951-thumbnail.jpg?width=320&height=320&fit=bounds slideshow/rennert-et-al-ash-2019-talk/204579591 Rennert et al. ASH 201...